New combo therapy tested for Tough-to-Treat lung cancer
NCT ID NCT04607954
Summary
This study is testing whether combining two drugs, durvalumab and lurbinectedin, can help control cancer growth in people with extensive stage small cell lung cancer that has come back or stopped responding to their first treatment. The trial aims to see if this combination can keep the cancer from getting worse for at least six months and help patients live longer. It is for adults whose cancer progressed after initial chemotherapy and immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT LUNG SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.